stockportfolio.pro
Nuvalent, Inc. (NUVL)
Healthcare · Biotechnology · NasdaqGS
Nuvalent, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-14.56M | $-46.34M | $-81.85M | $-126.22M | $-260.76M | $-425.38M |
| Net margin | — | — | — | — | — | — |
Source: Nuvalent, Inc. SEC filings (10-K).
Explore 6 years of Nuvalent, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NUVL in your portfolio →
Nuvalent, Inc. financial history by metric
About Nuvalent, Inc.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. — frequently asked questions
What is Nuvalent, Inc.'s revenue?
Nuvalent, Inc. (NUVL) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Nuvalent, Inc. profitable?
No — NUVL reported a net loss of $-425.38M in fiscal 2025.
What is NUVL's P/E ratio?
Nuvalent, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Nuvalent, Inc. have?
As of fiscal year 2025, NUVL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Nuvalent, Inc.'s market cap?
Nuvalent, Inc. (NUVL) has a market capitalization of about $9.75B, based on the latest data in our nightly-refreshed cache.
When does Nuvalent, Inc.'s fiscal year end?
NUVL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Nuvalent, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.